Gingival hyperplasia in dogs induced by oxodipine, a calcium channel blocking agent.
Subchronic oral exposure of dogs to Oxodipine, a new calcium channel blocker of the dihydropyridine-type, resulted in dose-related gingival hyperplastic changes. The doses at which an effect was elicited were 24 and 73 times the intended therapeutic dose for man. The effects were first noted after 7 weeks of treatment, and were limited to the high and intermediate dose groups of both sexes. Macroscopically, a generalized enlargement of the maxillary and mandibular facial and lingual gingivae were noted. The histological changes were similar to those described in man for Nifedipine and hydantoin-related drugs. An increase in the activity of alkaline phosphatase and a decrease in alanine aminotransferase was demonstrated. This article is the first to describe gingival hyperplasia in dogs induced in a dose-dependent manner by a calcium channel blocker.
Waner
T
T
Life Science Research Israel, Ness Ziona.
Nyska
A
A
Nyska
M
M
Pirak
M
M
Sela
M
M
Galiano
A
A
D000410:Alanine Transaminase / Q000032:analysis; D000469:Alkaline Phosphatase / Q000032:analysis; D000818:Animals; D002121:Calcium Channel Blockers / Q000633:toxicity*; D004095:Dihydropyridines / Q000633:toxicity*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D005881:Gingiva / Q000201:enzymology / Q000473:pathology; D005885:Gingival Hyperplasia / Q000139:chemically induced*; D008297:Male; D009543:Nifedipine / Q000633:toxicity
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; C053783:oxodipine; D009543:Nifedipine